National laboratory surveillance of Invasive streptococcal disease in Canada - Annual summary 2018

Executive summary

Figure A. Invasive S. pneumoniae serotypes in all ages

Figure A

* Component of PCV7; ** Component of PCV13; ^ Component of PPV23; ‡ Number of isolates for 2014, 2015, 2016, 2017 and 2018 respectively.

Figure A - Text description

Bar graph displaying the percentage of Streptococcus pneumonia serotypes from 2014 to 2018 based on the total number of isolates tested annually.

Column Labels 2014 (n=2564) 2015 (n=2689) 2016 (n=2808) 2017 (n=3223) 2018 (n=3279)
4* (57,103,182,234,205)‡ 2.2% 3.8% 6.5% 7.3% 6.3%
6B* (5,10,20,9,8) 0.2% 0.4% 0.7% 0.3% 0.2%
9V* (9,7,5,15,35) 0.4% 0.3% 0.2% 0.5% 1.1%
14* (12,12,16,29,13) 0.5% 0.4% 0.6% 0.9% 0.4%
18C* (6,6,9,8,4) 0.2% 0.2% 0.3% 0.2% 0.1%
19F* (25,47,46,90,74) 1.0% 1.7% 1.6% 2.8% 2.3%
23F* (10,8,4,2,2) 0.4% 0.3% 0.1% 0.1% 0.1%
1** (3,4,4,0,0) 0.1% 0.1% 0.1% 0.0% 0.0%
3** (223,235,267,309,390) 8.7% 8.7% 9.5% 9.6% 11.9%
5** (0,3,0,0,0) 0.0% 0.1% 0.0% 0.0% 0.0%
6A** (17,9,19,7,14) 0.7% 0.3% 0.7% 0.2% 0.4%
7F** (184,145,109,115,106) 7.2% 5.4% 3.9% 3.6% 3.2%
19A** (221,213,176,159,175) 8.6% 7.9% 6.3% 4.9% 5.3%
2^ (0,0,0,1,2) 0.0% 0.0% 0.0% 0.0% 0.1%
8^ (105,139,148,156,186) 4.1% 5.2% 5.3% 4.8% 5.7%
9N^ (109,115,138,213,188) 4.3% 4.3% 4.9% 6.6% 5.7%
10A^ (60,47,48,64,62) 2.3% 1.7% 1.7% 2.0% 1.9%
11A^ (117,97,91,93,117) 4.6% 3.6% 3.2% 2.9% 3.6%
12F^ (88,128,102,126,160) 3.4% 4.8% 3.6% 3.9% 4.9%
15B/C^(83,87,126,123,103) 3.2% 3.2% 4.5% 3.8% 3.1%
17F^ (32,22,29,37,37) 1.2% 0.8% 1.0% 1.1% 1.1%
20^ (70,90,81,117,127) 2.7% 3.3% 2.9% 3.6% 3.9%
22F^ (282,252,255,280,285) 11.0% 9.4% 9.1% 8.7% 8.7%
33F^ (59,89,98,105,94) 2.3% 3.3% 3.5% 3.3% 2.9%
6C (91,78,73,66,58) 3.5% 2.9% 2.6% 2.0% 1.8%
6D (2,3,0,0,0) 0.1% 0.1% 0.0% 0.0% 0.0%
7A (0,1,0,0,0) 0.0% 0.0% 0.0% 0.0% 0.0%
7B (1,2,0,2,0) 0.0% 0.1% 0.0% 0.1% 0.0%
7C (20,30,43,28,57) 0.8% 1.1% 1.5% 0.9% 1.7%
9A (0,2,0,0,1) 0.0% 0.1% 0.0% 0.0% 0.0%
9L (0,0,2,3,2) 0.0% 0.0% 0.1% 0.1% 0.1%
10B (4,2,2,2,3) 0.2% 0.1% 0.1% 0.1% 0.1%
10F (1,0,2,3,2) 0.0% 0.0% 0.1% 0.1% 0.1%
11B (2,6,3,0,0) 0.1% 0.2% 0.1% 0.0% 0.0%
11C (0,0,0,0,1) 0.0% 0.0% 0.0% 0.0% 0.0%
11D (0,0,0,3,0) 0.0% 0.0% 0.0% 0.1% 0.0%
12A (0,0,0,0,4) 0.0% 0.0% 0.0% 0.0% 0.1%
12B (0,0,0,1,0) 0.0% 0.0% 0.0% 0.0% 0.0%
13 (12,7,9,6,10) 0.5% 0.3% 0.3% 0.2% 0.3%
15A (111,119,123,152,128) 4.3% 4.4% 4.4% 4.7% 3.9%
16F (96,73,72,77,70) 3.7% 2.7% 2.6% 2.4% 2.1%
17A (0,1,0,0,0) 0.0% 0.0% 0.0% 0.0% 0.0%
18A (1,0,1,0,0) 0.0% 0.0% 0.0% 0.0% 0.0%
18F (0,0,1,0,2) 0.0% 0.0% 0.0% 0.0% 0.1%
21 (6,14,12,20,15) 0.2% 0.5% 0.4% 0.6% 0.5%
22A (4,1,0,1,0) 0.2% 0.0% 0.0% 0.0% 0.0%
23A (108,110,107,152,112) 4.2% 4.1% 3.8% 4.7% 3.4%
23B (85,85,83,101,116) 3.3% 3.2% 3.0% 3.1% 3.5%
24 (1,2,1,0,1) 0.0% 0.1% 0.0% 0.0% 0.0%
24A (0,0,1,0,1) 0.0% 0.0% 0.0% 0.0% 0.0%
24B (1,2,1,1,2) 0.0% 0.1% 0.0% 0.0% 0.1%
24F (14,20,23,27,23) 0.5% 0.7% 0.8% 0.8% 0.7%
25A (0,0,0,0,1) 0.0% 0.0% 0.0% 0.0% 0.0%
25F (1,0,0,0,0) 0.0% 0.0% 0.0% 0.0% 0.0%
27 (0,0,0,0,1) 0.0% 0.0% 0.0% 0.0% 0.0%
28A (1,3,5,10,10) 0.0% 0.1% 0.2% 0.3% 0.3%
29 (13,15,10,4,6) 0.5% 0.6% 0.4% 0.1% 0.2%
31 (40,36,50,51,54) 1.6% 1.3% 1.8% 1.6% 1.6%
32A (0,0,0,2,0) 0.0% 0.0% 0.0% 0.1% 0.0%
33A (3,10,4,2,0) 0.1% 0.4% 0.1% 0.1% 0.0%
33B (0,0,1,0,0) 0.0% 0.0% 0.0% 0.0% 0.0%
33C (0,0,0,1,0) 0.0% 0.0% 0.0% 0.0% 0.0%
34 (22,27,30,28,33) 0.9% 1.0% 1.1% 0.9% 1.0%
35A (2,1,4,2,0) 0.1% 0.0% 0.1% 0.1% 0.0%
35B (51,61,62,78,74) 2.0% 2.3% 2.2% 2.4% 2.3%
35C (1,1,0,0,0) 0.0% 0.0% 0.0% 0.0% 0.0%
35F (60,64,56,50,44) 2.3% 2.4% 2.0% 1.6% 1.3%
37 (4,2,2,2,1) 0.2% 0.1% 0.1% 0.1% 0.0%
38 (21,37,46,51,51) 0.8% 1.4% 1.6% 1.6% 1.6%
42 (0,0,0,1,0) 0.0% 0.0% 0.0% 0.0% 0.0%
NT (8,6,6,4,9) 0.3% 0.2% 0.2% 0.1% 0.3%

Figure B. Annual trend of multi-drug resistance of S. pneumoniae

Figure B.

* Antimicrobial classes include: β-lactams (amoxicillin/clavulanic acid, penicillin using meninigitis breakpoints, ceftriaxone using meningitis breakpoints, cefuroxime using parenteral breakpoint, ertapenem, imipenem and meropenem); macrolides (clarithromycin); fluoroquinolones (levofloxacin and moxifloxacin); tetracyclines (doxycycline); folate pathway inhibitors (trimethoprim-sulfamethoxazole); phenicols (chloramphenicol); lincosamides (clindamycin); oxazolidinones (linezolid).

Figure B - Text description

A combination line and stacked bar graph displaying multidrug resistance trends from 2014 to 2018 for Streptococcus pneumoniae

Category 1 Resistant to 7 classes* Resistant to 6 classes Resistant to 5 classes Resistant to 4 classes Resistant to 3 classes Resistant to 2 classes Resistant to 1 class Resistant to ≥3 classes
2014 (n=1116) 0.0% 0.5% 1.0% 1.5% 2.0% 8.3% 18.3% 5.0%
2015 (n=1128) 0.0% 0.0% 1.8% 2.6% 2.4% 5.2% 18.4% 6.7%
2016 (n=1114) 0.0% 0.1% 0.8% 2.8% 2.5% 6.4% 18.2% 6.2%
2017 (n=1129) 0.0% 0.4% 1.5% 4.6% 3.1% 6.1% 19.5% 9.6%
2018 (n=1792) 0.0% 0.9% 2.1% 2.2% 2.4% 6.1% 22.1% 7.6%

Figure C. Invasive S. pyogenes emm types

Figure C.

† Number of isolates from 2014, 2015, 2016, 2017 and 2018, respectively.

Figure C - Text description

Bar graph displaying emm types of Streptococcus pyogenes from 2014 to 2018 by percentage based on the total number of isolates tested annually.

Column1 2014 (n=1704) 2015 (n=1760) 2016 (n=2154) 2017 (n=2473) 2018 (n=3202)
1 (456,317,323,449,547)† 26.8% 18.0% 15.0% 18.2% 17.1%
2 (46,39,31,33,53) 2.7% 2.2% 1.4% 1.3% 1.7%
3 (37,150,132,61,88) 2.2% 8.5% 6.1% 2.5% 2.7%
4 (99,86,98,86,100) 5.8% 4.9% 4.5% 3.5% 3.1%
5 (9,8,11,7,11) 0.5% 0.5% 0.5% 0.3% 0.3%
6 (80,41,57,48,109) 4.7% 2.3% 2.6% 1.9% 3.4%
8 (2,0,1,0,2) 0.1% 0.0% 0.0% 0.0% 0.1%
9 (10,11,11,41,45) 0.6% 0.6% 0.5% 1.7% 1.4%
11 (55,85,64,68,72) 3.2% 4.8% 3.0% 2.7% 2.2%
12 (108,128,137,147,145) 6.3% 7.3% 6.4% 5.9% 4.5%
13 (0,0,0,0,3) 0.0% 0.0% 0.0% 0.0% 0.1%
18 (0,0,5,4,3) 0.0% 0.0% 0.2% 0.2% 0.1%
22 (18,26,25,25,30) 1.1% 1.5% 1.2% 1.0% 0.9%
25 (1,2,3,1,4) 0.1% 0.1% 0.1% 0.0% 0.1%
28 (107,92,97,126,164) 6.3% 5.2% 4.5% 5.1% 5.1%
33 (1,0,0,0,3) 0.1% 0.0% 0.0% 0.0% 0.1%
41 (36,44,37,55,47) 2.1% 2.5% 1.7% 2.2% 1.5%
44 (6,3,4,4,9) 0.4% 0.2% 0.2% 0.2% 0.3%
48 (1,3,5,4,3) 0.1% 0.2% 0.2% 0.2% 0.1%
49 (1,3,12,70,99) 0.1% 0.2% 0.6% 2.8% 3.1%
53 (45,57,26,37,131) 2.6% 3.2% 1.2% 1.5% 4.1%
58 (3,9,22,14,10) 0.2% 0.5% 1.0% 0.6% 0.3%
59 (31,24,49,57,35) 1.8% 1.4% 2.3% 2.3% 1.1%
63 (1,0,1,2,5) 0.1% 0.0% 0.0% 0.1% 0.2%
64 (0,0,0,1,3) 0.0% 0.0% 0.0% 0.0% 0.1%
68 (43,31,40,25,24) 2.5% 1.8% 1.9% 1.0% 0.7%
73 (10,9,8,15,7) 0.6% 0.5% 0.4% 0.6% 0.2%
74 (0,9,172,234,372) 0.0% 0.5% 8.0% 9.5% 11.6%
75 (21,23,33,41,60) 1.2% 1.3% 1.5% 1.7% 1.9%
76 (10,9,8,73,205) 0.6% 0.5% 0.4% 3.0% 6.4%
77 (18,36,36,33,64) 1.1% 2.0% 1.7% 1.3% 2.0%
78 (0,0,0,0,3) 0.0% 0.0% 0.0% 0.0% 0.1%
80 (33,26,22,9,9) 1.9% 1.5% 1.0% 0.4% 0.3%
81 (30,113,160,226,200) 1.8% 6.4% 7.4% 9.1% 6.2%
82 (23,60,104,63,68) 1.3% 3.4% 4.8% 2.5% 2.1%
83 (19,24,32,37,57) 1.1% 1.4% 1.5% 1.5% 1.8%
87 (37,29,37,29,40) 2.2% 1.6% 1.7% 1.2% 1.2%
89 (159,112,107,136,144) 9.3% 6.4% 5.0% 5.5% 4.5%
90 (1,2,0,2,3) 0.1% 0.1% 0.0% 0.1% 0.1%
91 (15,25,38,34,27) 0.9% 1.4% 1.8% 1.4% 0.8%
92 (4,2,3,14,63) 0.2% 0.1% 0.1% 0.6% 2.0%
93 (1,1,3,4,2) 0.1% 0.1% 0.1% 0.2% 0.1%
94 (4,4,7,5,11) 0.2% 0.2% 0.3% 0.2% 0.3%
101 (52,42,110,87,50) 3.1% 2.4% 5.1% 3.5% 1.6%
102 (1,7,5,8,8) 0.1% 0.4% 0.2% 0.3% 0.2%
103 (0,2,0,0,2) 0.0% 0.1% 0.0% 0.0% 0.1%
110 (0,0,2,1,3) 0.0% 0.0% 0.1% 0.0% 0.1%
112 (0,2,0,2,2) 0.0% 0.1% 0.0% 0.1% 0.1%
114 (11,14,17,8,19) 0.6% 0.8% 0.8% 0.3% 0.6%
118 (25,23,29,8,15) 1.5% 1.3% 1.3% 0.3% 0.5%
168 (0,0,0,0,4) 0.0% 0.0% 0.0% 0.0% 0.1%
169 (1,1,2,9,4) 0.1% 0.1% 0.1% 0.4% 0.1%
Other (33,26,28,30,15) 1.9% 1.5% 1.3% 1.2% 0.5%
Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: